{"id":"https://genegraph.clinicalgenome.org/r/b0d73d77-a58e-4cb3-af84-800f712b23d0v1.0","type":"EvidenceStrengthAssertion","dc:description":"HPS1 was first reported in relation to Autosomal Recessive Hermasky-Pudlak syndrome 1 in 1996 \n(Oh et al., PMID: 8896559). At least 36 unique variants including missense, in-frame indel, nonsense, frameshift, and large deletions have been reported in humans. HPS1 is involved in organelle biogenesis associated with melanosomes, platelet dense granules, and lysosomes. Hermansky-Pudlak syndrome 1 is characterized by severe oculocutaneous albinism and a bleeding diathesis, but in some cases, also pulmonary fibrosis and granulomatous colitis. Evidence supporting this gene-disease relationship includes case-level data and experimental data.  \n  \nSummary of Case Level Data: 12 Points \nVariants in this gene have been reported in at least 10 probands in 4 publications (PMIDs: 8896559, 9497254, 9705234, 27593200). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. \n  \nThe mechanism for disease is homozygous loss of function (PMID: 9256466)  \t \n  \nSummary of Experimental Data: 5.5 Points \nThis gene-disease association is supported by mouse models and in vitro functional assays. The \"pale ear\" or ep mouse that carries a spontaneously occurring mutation in Hps1 recapitulates the human HPS phenotype (PMID: 9256466, 9158155). HPS1 interacts with HPS4 to form BLOC-3, which is involved in the biogenesis of lysosome-related organelles (PMID: 12847290, 29190429, 25468649).  \n\nIn summary, HPS1 is definitively associated with Autosomal Recessive Hermasky-Pudlak syndrome 1. \nThis has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Hemostasis/Thrombosis GCEP on June 26, 2019 (SOP Version 6).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/b0d73d77-a58e-4cb3-af84-800f712b23d0","GCISnapshot":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2019-07-22T14:28:42.174Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fcbc2495-02e6-46d3-809d-731ff3194a99_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was homozygous for the 4-bp duplication that causes a frameshift and early termination of translation at amino acid position, 582. The parents were verified to be heterozygous for the variant. This variant is absent from gnomAD.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aaf7586b-b701-47f4-a492-80528defc1a3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27593200","rdfs:label":"Wei_Patient 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"NGS by a mutational screening panel of 100 hypopigmentation genes. Variants were verified subsequently by Sanger.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"The proband is noted to have white skin, brownish-yellow hair color at birth, brown iris color, flat foveae, absence of platelet dense granules, a history of skin bruises, and oculocutaneous albinism - 2.","phenotypes":["obo:HP_0000978","obo:HP_0000639"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/fcbc2495-02e6-46d3-809d-731ff3194a99_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27593200","allele":{"id":"https://genegraph.clinicalgenome.org/r/4453799e-98e4-4b28-a137-46a4ea1a171e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.5(HPS1):c.1457_1460dup (p.Thr488SerfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913187505"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4929ebdd-b538-4c0c-b261-450a94b61fdd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The 16-bp duplication is the most common pathogenic founder variant seen in Puerto Rico patients. It causes a frameshift and results in early termination at amino acid position, 586. In this study, it was observed in the homozygous state in 22 patients and in the heterozygous state in 11 carriers. It is reported in 7/35412 Latino alleles, with no homozygotes, in gnomAD. GeneReviews reports that at least 255 individuals with variant have been reported, as of July, 2017.\n\nPMID: 9562579 by Gahl et al. also reports on this variant in 25 homozygous Puerto Rican patients diagnosed with HPS on the basis of the presence of oculocutaneous albinism and a storage-pool deficiency.\n\nNote: The variant is reported in the paper as a frameshift occurring at amino acid position Pro496. Per HGVS, this occurs at His497.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/194148d1-8abd-4035-9144-41e85de3398f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8896559","rdfs:label":"Oh_Proband_Puerto Rico","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"The 16-bp mutation was detected by SSCP analysis and DNA sequencing. The authors note that this mutation was also detected by PCR followed by Agarose gel electrophoresis.","firstTestingMethod":"SSCP","phenotypeFreeText":"The proband is noted to have been diagnosed with HPS.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4929ebdd-b538-4c0c-b261-450a94b61fdd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8896559","allele":{"id":"https://genegraph.clinicalgenome.org/r/162e181e-5ed9-4ce5-912a-835ad18aeaeb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.1472_1487dup16 (p.His497Glnfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5277"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3d0277c9-0ec9-4d83-b8b0-1f9b70dd7157_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was homozygous for an in-frame, single amino acid deletion of Ile at position 55. The variant is not reported in gnomAD.\n\nNote: The variant is reported as I55 in the paper. Per HGVS, the variant is I56.\n\nThis proband is scored reduced points in the absence of functional variant evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cbccaf50-7c68-4745-bc08-21c049d9062a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","rdfs:label":"Oh_Patient No.10","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Mutations in HPS1 were detected by SSCP analysis and direct sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient is noted to have a very mild HPS phenotype.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3d0277c9-0ec9-4d83-b8b0-1f9b70dd7157_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","allele":{"id":"https://genegraph.clinicalgenome.org/r/433d29ef-3b21-43ce-b19c-56f6cf40075d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.166_168delATC (p.Ile56del)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21095"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a3ef7e2a-bdb5-485d-ab4b-6b7e4429e6c1_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was homozygous for a 1-bp deletion that causes a frameshift and early termination at amino acid position 398. The variant is reported in gnomAD in 19/128472 non-Finnish European alleles with no homozygotes.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e0e4a1da-692c-4f13-a374-1a71242d8b85","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","rdfs:label":"Oh_Patient No.5","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Mutations in HPS1 were detected by SSCP analysis and direct sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient is noted to have severe HPS1","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/a3ef7e2a-bdb5-485d-ab4b-6b7e4429e6c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","allele":{"id":"https://genegraph.clinicalgenome.org/r/c05984f6-51d6-46f1-aad1-09492bd08bfa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.3(HPS1):c.1189delC (p.Gln397Serfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21091"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/cf3a3acc-f9e4-43d4-9b4f-9556bda2e263_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was compound heterozygous for a splice site variant, c.398+5G>A, inherited from the mother, and a 1-bp deletion, 1691delA, causing a frameshift and early termination of translation, inherited from the father. Neither variant is reported in gnomAD. (This evidence was curated by Loredana Bury)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb03e027-96a4-40b9-8334-5924db86968f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16185271","rdfs:label":"Ito_Proband","ageType":"AgeAtReport","ageUnit":"Months","ageValue":3,"detectionMethod":"DNA segments spanning each of the 20 HPS1 genomic exons were screened\nfor mutations SSCP/heteroduplex method. Two kinds of SSCP gels, with glycerol concentrations of 7% and 10%, were used. PCR products showing aberrant patterns were reamplified and sequenced.","firstTestingMethod":"SSCP","phenotypes":["obo:HP_0006934","obo:HP_0001022","obo:HP_0001892"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/cf3a3acc-f9e4-43d4-9b4f-9556bda2e263_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16185271","allele":[{"id":"https://genegraph.clinicalgenome.org/r/768c530a-0933-4beb-a0df-d1d6fb2935db","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.1691delA (p.Lys564Argfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21096"}},{"id":"https://genegraph.clinicalgenome.org/r/3cba1de4-94c3-4aa7-82c2-2503e3dbfdd6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.398+5G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5283"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/fa60acbb-6014-409e-90ef-bd02ec2fa787_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The patient was compound heterozygous for two 1-bp deletions that cause frameshifts and subsequent early termination. Both variants are reported at very low frequencies in gnomAD.\n\nThis evidence is not scored any points as there is no report of parental testing or evidence that the two variants are in trans.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef4978bc-8ec2-4840-ba56-18cf8c4d2aba","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","rdfs:label":"Oh_Patient No.6","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Mutations in HPS1 were detected by SSCP analysis and direct sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient is noted to have a typical HPS phenotype.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/fa60acbb-6014-409e-90ef-bd02ec2fa787_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","allele":[{"id":"https://genegraph.clinicalgenome.org/r/219bff39-4bbd-4a97-a307-6d44867c1173","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.962delG (p.Gly321Alafs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21110"}},{"id":"https://genegraph.clinicalgenome.org/r/c05984f6-51d6-46f1-aad1-09492bd08bfa"}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b3a8af14-e168-43b3-88da-5861dddd91da_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was homozygous for a 1-bp deletion at the same poly-C tract as a previously reported 1-bp duplication. The deletion causes a frameshift and early termination of translation at amino acid position 330. It is reported in gnomAD at a frequency of 0.0008594 with no homozygotes.\n\nNote: The variant is reported as T322delC in the report. per HGVS, it is Met325Trpfs.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fde0e808-ab46-45f2-9df2-c7bfef43df86","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","rdfs:label":"Oh_Patient No.8","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Mutations in HPS1 were detected by SSCP analysis and direct sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient is noted to have a typical HPS phenotype.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/b3a8af14-e168-43b3-88da-5861dddd91da_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd03cdb3-4c1e-4c8b-9503-e4d6b0992e59","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.972delC (p.Met325Trpfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5280"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/bf700772-3292-4d9e-905f-a01af35897cf_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was compound heterozygous for 2 previously reported 1-bp deletions: one at the poly-C tract, c.972del, inherited from the father, and the other, c.1189delC, inherited from the mother. The deletions cause frameshifts and early termination of translation. Both deletions are reported in gnomAD at low frequencies with no homozygotes.\n\nNorthern blot analysis on fibroblasts from the proband showed an absence of HPS1 RNA.\n\nThe proband is scored default points. Note, the variants have been individually awarded points previously, for probands from other reports.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9dd9eb2b-c617-4d21-a25c-d8db234747b2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9705234","rdfs:label":"Shotelersuk_Patient 39","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"detectionMethod":"PCR amplicons were directly sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"Diagnosis of HPS was made at 1y of age. Prolonged epistaxes reported at ages 6, 13 and 14. Visual acuity in each eye was 20/200. There was marked transillumination and some pigmentation of the iris. Fundus hypopigmentation was seen in the periphery. Macula was not transparent. Platelet count: 1999,000/mme+3","phenotypes":["obo:HP_0000978","obo:HP_0000666","obo:HP_0004406","obo:HP_0007894","obo:HP_0007750","obo:HP_0006934","obo:HP_0000577","obo:HP_0001583"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/bf700772-3292-4d9e-905f-a01af35897cf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9705234","allele":[{"id":"https://genegraph.clinicalgenome.org/r/dd03cdb3-4c1e-4c8b-9503-e4d6b0992e59"},{"id":"https://genegraph.clinicalgenome.org/r/c05984f6-51d6-46f1-aad1-09492bd08bfa"}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/eb5efa1e-ff41-4250-b0e6-564956c30940_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband and five other HPS patients of Swiss Alpine origin were found to be homozygous for the 1-bp duplication that causes a frameshift and early termination at amino acid position 452. The 12 obligate carriers studied were determined to be heterozygous. It is not reported in gnomAD.\n\nThis variant was also detected in a non-inbred Irish HPS patient in the homozygous state.\n\nThe authors conclude that the variants arose independently in the two populations by analyzing two missense polymorphisms found in the Swiss patients (one seen in linkage with this variant), which were absent in the Irish patient.\n\nNote: The variant is reported in the paper as a frameshift occurring at amino acid position Pro324. Per HGVS, this occurs at Met325.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a821614-a2f6-4b07-8df1-6f523f5b07ae","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8896559","rdfs:label":"Oh_Proband_Swiss","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"The mutation was detected by SSCP and DNA sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The proband was noted to have been diagnosed with HPS","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/eb5efa1e-ff41-4250-b0e6-564956c30940_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8896559","allele":{"id":"https://genegraph.clinicalgenome.org/r/60b5ff18-38c0-4579-bb6f-58caa9712c88","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.972dupC (p.Met325Hisfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5278"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ebbb9ce0-e12c-4694-b0a3-cba4d62b0823_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was compound heterozygous for two missense variants: Leu668Pro, inherited from the father, and Arg106Gly, inherited from the mother.\n\nThe Arg106Gly variant is predicted deleterious by in-silico tools. Experimental evidence for the Leu668Pro variant is available from PMID: 16185271: Ito et al. show that overexpression of the variant HPS1 in HPS4-mutant (HPS1 interacts with HPS4 to form the BLOC-3 complex) mouse melanocytes failed to restore stabilization of HPS4, while the same was achieved by wild-type HPS1, indicating that the variant resulted in the loss of HPS1 protein function.\n\nThe evidence is scored reduced points as functional evidence is available for one variant only.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21a66dd9-61c5-4c28-a889-f60ddfb5ce4b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27593200","rdfs:label":"Wei_Patient 4","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"detectionMethod":"NGS by a mutational screening panel of 100 hypopigmentation genes. Variants were verified subsequently by Sanger.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"The proband is noted to have white skin, brownish-black hair color at birth, brownish-black iris color, flat foveae, absence of platelet dense granules, a history of skin bruises, a bleeding episode after an inguinal hernia surgery, and oculocutaneous albinism - 2.","phenotypes":["obo:HP_0000639","obo:HP_0004846","obo:HP_0000978"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ebbb9ce0-e12c-4694-b0a3-cba4d62b0823_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27593200","allele":[{"id":"https://genegraph.clinicalgenome.org/r/79bc7b8f-7518-46d0-9904-256b37fa7d76","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.2003T>C (p.Leu668Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21101"}},{"id":"https://genegraph.clinicalgenome.org/r/93fa679e-9e70-4f78-945b-31f32b9654a3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.5(HPS1):c.316C>G (p.Arg106Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5639434"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cfee8e0b-bdac-4c1a-8186-88918680306f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was homozygous for a +5 splice site variant. RT-PCR analysis from proband lymphocytes showed that the mutation resulted in a 17bp deletion and frameshift Tyr81Leufs*38. The variant is not in gnomAD and is scored default for null variant. (This evidence was curated by Loredana Bury)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ed757bb8-359c-4182-98c6-891467029b8d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27942505","rdfs:label":"Ghafouri-Fard_Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":22,"detectionMethod":"Genomic DNA was extracted from peripheral blood leukocytes of the patient after informed consent using the standard salting out method. Sequence analysis was performed using NimbleGen chip capturing of 15 Albinism related genes including GPR143, MITF, OCA2, SLC45A2, TYR and HPS1 followed by next generation sequencing (BGI-Clinical Laboratories, Shenzhen, China).","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0000613","obo:HP_0000978","obo:HP_0007663","obo:HP_0001010","obo:HP_0006934"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/cfee8e0b-bdac-4c1a-8186-88918680306f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27942505","allele":{"id":"https://genegraph.clinicalgenome.org/r/08cc7cc3-36ee-47f5-ae0d-0dcf4c368df0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.5(HPS1):c.255+5G>A (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913189046"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7126d924-8575-4099-a908-3a9089e78a09_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The 1-bp duplication was found in the homozygous state in an inbred Japanese patient. The duplication results in a frameshift and subsequent early termination at amino acid position, 452. The variant is not reported in gnomAD. It is awarded default points though the authors note that the parents were unavailable for testing, since a large deletion on the other allele is likely to be damaging as well.\n\nNote: The variant is reported in the paper as a frameshift occurring at amino acid position Ala441. Per HGVS, this occurs at Gln442.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/156f234f-5ae2-40e3-b366-d16ddd9cb022","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8896559","rdfs:label":"Oh_Proband_Japan","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient was reported to be diagnosed with HPS.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/7126d924-8575-4099-a908-3a9089e78a09_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8896559","allele":{"id":"https://genegraph.clinicalgenome.org/r/47f3204d-297c-4a7d-889b-35061b9a5132","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.1323dupA (p.Gln442Thrfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21092"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/798331f7-4b2d-48c2-828e-4e62bedc79cc_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was homozygous for the splice region variant at a conserved nucleotide, c.398+5G>A. The variant is expected to alter splicing. The variant is not found in gnomAD. It has also been reported in compound heterozygous state with a 1-bp duplication, c.962dupG, in a Japanese male with oculocutaneous albinism and a bleeding diathesis by Horikawa et al. (PMID: 10971344).\n\nThe evidence is awarded reduced points as the variant is expected to cause alteration of splicing, but the impact is not clearly determined.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2bc3135d-0703-4701-9986-696190129a8a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","rdfs:label":"Oh_Patient No.9","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Mutations in HPS1 were detected by SSCP analysis and direct sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient is noted to have a typical HPS phenotype.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/798331f7-4b2d-48c2-828e-4e62bedc79cc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","allele":{"id":"https://genegraph.clinicalgenome.org/r/3cba1de4-94c3-4aa7-82c2-2503e3dbfdd6"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/94d9afa1-969a-4e66-ae95-ea565399352c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was compound heterozygous for the \"hot spot\" variant, Met325Hisfs, and a novel nonsene variant, Glu666Ter. Neither variant is reported in gnomAD.\n\nThis evidence is not scored any points as there is no report of parental testing or evidence that the two variants are in trans.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c42f2cd-758e-47a1-bb65-a7489f81a05b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","rdfs:label":"Oh_Patient No.4","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Mutations in HPS1 were detected by SSCP analysis and direct sequencing.","firstTestingMethod":"SSCP","phenotypeFreeText":"The proband is noted to have mild HPS1","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/94d9afa1-969a-4e66-ae95-ea565399352c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9497254","allele":[{"id":"https://genegraph.clinicalgenome.org/r/3005f3f8-0588-4a5e-aff6-3bf2d4c0ee4a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.3(HPS1):c.1996G>T (p.Glu666Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5279"}},{"id":"https://genegraph.clinicalgenome.org/r/60b5ff18-38c0-4579-bb6f-58caa9712c88"}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/484d10b8-0366-4fd3-aab1-03688f0a0204_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The proband was compound heterozygous for a nonsense variant, Glu133Ter, and a previously reported 1-bp insertion that causes a frameshift and early termination, Met325Hisfs. Sequencing of cDNA subclones from RT-PCR showed that the two variants were in trans. Northern blot revealed absence of HPS1 RNA in proband's fibroblasts.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0158053-197e-435d-9513-4ab50095a668","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9705234","rdfs:label":"Shotelersuk_Patient 31","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"PCR amplicons were directly sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"Proband is noted to have been born with pale skin. Oculocutaneous albinism was diagnosed at 3m of age. HPS was diagnosed at 18m of age based on abnormal platelet aggregation. Epistaxis occurred in winter, prolonged bleeding was seen with a cut lip and myringotomy tube placement.\n\nHer hair was straw-colored and skin was fair. Visual acuity in each eye was 20/100, with moderate hyperopic astigmatic correction. Moderate iris pigmentation in each eye and moderate macular transparency were seen. Platelet count was 311,000/mme+3.","phenotypes":["obo:HP_0000980","obo:HP_0000421","obo:HP_0000639","obo:HP_0000577","obo:HP_0001934","obo:HP_0001107","obo:HP_0000978","obo:HP_0007894","obo:HP_0000666","obo:HP_0007750","obo:HP_0002099"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/484d10b8-0366-4fd3-aab1-03688f0a0204_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9705234","allele":[{"id":"https://genegraph.clinicalgenome.org/r/479566e2-1c8a-490a-9608-9f3d79f65b2d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000195.4(HPS1):c.397G>T (p.Glu133Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5281"}},{"id":"https://genegraph.clinicalgenome.org/r/60b5ff18-38c0-4579-bb6f-58caa9712c88"}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/30197d75-c201-4fea-87ce-59ecd2db1835","type":"EvidenceLine","dc:description":"The mouse model is awarded increased points as two mutations have been shown as causative in the ep mice on different backgrounds. The MGI lists 40 publications associated with the ep mouse model (http://www.informatics.jax.org/reference/allele/MGI:1856712?typeFilter=Literature ).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5b6e9732-4082-42a6-9692-bca62db4e5fb","type":"Finding","dc:description":"The \"pale ear\" mouse is a spontaneously occurring mutation in mice that recapitulates the HPS1 phenotype.\n\nIn this paper, the authors show that normal and homozygous mutant mRNA transcripts differed on the order of 600 nucleotides, upon Northern blot analysis. Melanosomes from ep mice were found to be larger than those from wild-type mice. Platelets from ep mice showed very few dense bodies, abnormal aggregation with collagen and reduced ATP release","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9256466","rdfs:label":"Gardner_Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/a6999e92-332a-4638-8667-786a8f28993a","type":"EvidenceLine","dc:description":"The evidence is awarded increased points for showing the correction of the cellular function as well as phenotype in the melanocytes.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e5f538b-5096-4f6d-88fc-87e36fe6af61","type":"Finding","dc:description":"FACS and qPCR analyses showed efficient gene transfer. Western blot revealed HPS1 protein from normal (cells from healthy donor) as well LV-HPS1 HDM (52% of normal), while it was barely detectable in LV-GFP or affected (cells from HPS patients) HDM.\n\n(1) The correction of BLOC-3 formation was also confirmed based on the detection of HPS4 expression at a level 89% of that of normal.\n\n(2) Melanocyte pigmentation evaluated by pelleting and confocal microscopy was found to be increased in LV-HPS1 HDM compared to LV-GFP or non-transduced affected cells.\n\n(3) Intracellular localization of TYRP1 (melanogenic enzyme trafficking) was assessed by immunofluorescence. It showed that in wild-type cells, TYRP1 was localized to the Golgi region and to endosomes outside the Golgi region. In affected cell, TYRP1 remained in the trans-Golgi region, while it was decreased in the endosomes in the dendritic region. The LV-HPS1 HDM regained endosomal localization, similar to wild-type.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25468649","rdfs:label":"Ikawa_Rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3e62251-0692-4080-bf23-a4ae68593892","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff1c5829-883a-4a71-abce-fa223482d4c1","type":"FunctionalAlteration","dc:description":"The authors report that the MLE-15 cells preserved the AT-2 cell phenotype, related to lamellar-body-like organelles (lysosome-related organelles). MLE-15/HPS1 cells showed loss of RAB38 (lamellar body cargo protein) targeting to the organelles. MCP-1 (an important driver of macrophage alveolitis) RNA was significantly elevated in MLE-15/HPS1 cells. The authors suggest that this evidence is indicative of the injury to primary AT2 cells that result in pulmonary fibrosis in HPS patients and that MLE-15/HPS1 could form a cell model for HPS.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29190429","rdfs:label":"Kook_FunctionalAlteration"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f6d44a89-527f-4864-a1e1-dcd0a17000ca_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e39fb89b-98b7-4154-9946-1ff7d864d460","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c754d4a-9b6a-4a08-8ab3-49a0cf584609","type":"Finding","dc:description":"HPS1 and HPS4 are shown to interact to form the BLOC-3 complex. HPS1 mutations result in the reduction of HPS4 protein as well.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12847290","rdfs:label":"Nazarian_BiochmenicalFunctionA","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e07eca8e-f439-4f53-ae73-78ffdf43ae8e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb01d40e-41f3-4d59-8187-8eb5ae4d219d","type":"Finding","dc:description":"HPS1 and HPS4 proteins were analyzed by immunoprecipitation recapture in HeLA cell lysates. First immunoprecipitation with antibodies to HPS1 and subsequent second capture with antibodies to HPS4 revealed that the two two proteins coimmunoprecipitated. Correspondingly, when antibodies were swapped, the same was true.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12847290","rdfs:label":"Nazarian_ProteinInteraction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/66a9a329-9172-4898-b90a-11e250d802d6","type":"EvidenceLine","dc:description":"This interaction evidence has been scored previously. It is noted here for the record. (This evidence was curated by Loredana Bury)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28b46ace-0ae7-4c48-86dd-92cd92158787","type":"Finding","dc:description":"Co immunoprecipitation experiments demonstrated that epitope-tagged and endogenous HPS1 and HPS4 proteins assemble with each other in vivo and form a moderately asymmetric protein complex with a molecular mass of âˆ¼175 kDa. Therefore, the human HPS1 and HPS4 proteins are part of a complex named BLOC-3 that is involved in the biogenesis of lysosomal-related organelles","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12756248","rdfs:label":"Martina_Co-immunoprecipitation of HPS1 and HPS4","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5}],"evidenceStrength":"Definitive","sequence":54,"specifiedBy":"GeneValidityCriteria6","strengthScore":17.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/PjpFPAje-cs","type":"GeneValidityProposition","disease":"obo:MONDO_0008748","gene":"hgnc:5163","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_f6d44a89-527f-4864-a1e1-dcd0a17000ca-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}